N+1 Singer reaffirmed their hold rating on shares of Vernalis plc (LON:VER) in a report released on Monday. N+1 Singer currently has a GBX 28 ($0.36) price target on the stock.

VER has been the subject of several other research reports. Numis Securities Ltd restated an add rating and set a GBX 29 ($0.38) price target on shares of Vernalis plc in a research report on Friday, April 21st. Panmure Gordon downgraded shares of Vernalis plc to a hold rating and set a GBX 65 ($0.85) price target for the company. in a report on Friday, April 21st. Finally, Stifel Nicolaus cut their price target on shares of Vernalis plc from GBX 29 ($0.38) to GBX 24 ($0.31) and set a hold rating for the company in a report on Friday, April 21st. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Vernalis plc has an average rating of Hold and a consensus price target of GBX 39.40 ($0.51).

Shares of Vernalis plc (LON VER) traded down 2.94% on Monday, reaching GBX 16.50. 9,393 shares of the company’s stock traded hands. Vernalis plc has a 52 week low of GBX 15.98 and a 52 week high of GBX 49.75. The company has a 50 day moving average of GBX 18.14 and a 200-day moving average of GBX 22.39. The stock’s market capitalization is GBX 86.85 million.

ILLEGAL ACTIVITY WARNING: “Vernalis plc (VER) Stock Rating Reaffirmed by N+1 Singer” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/08/vernalis-plc-ver-stock-rating-reaffirmed-by-n1-singer.html.

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Analyst Recommendations for Vernalis plc (LON:VER)

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.